Establishment and Maintenance of DDLPS and Leiomyosarcoma Cell Lines

The DDLPS (IB115 and IB111) and leiomyosarcoma (IB136 and IB112) cell lines used in this study were derived from human surgical specimens (Institut Bergonié, Bordeaux, France) after obtaining patient consent. The MDM2 antagonist-resistant IB115 [P4] cell line was derived from IB115 cells through repeated exposure to the nutlin compound RG7388, as previously described [12 (link)]. Cells were maintained in RPMI medium 1640 (Sigma Life Technologies, St. Louis, MO, USA) with 10% fetal calf serum (Dutscher, France) in a humidified incubator containing 5% CO₂ maintained at 37 °C.

Free full text: Click here

Roy S., Laroche-Clary A., Verbeke S., Derieppe M.A, & Italiano A. (2020). MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies. Cancers, 12(8), 2253.

Publication 2020

fetal calf serum

Cell line Cells Fetal calf serum Human Leiomyosarcoma Mdm2 Patient Rg7388 Surgical

Corresponding Organization : Inserm

Top 5 similar protocols

Variable analysis

independent variables

Exposure to the nutlin compound RG7388

dependent variables

MDM2 antagonist resistance

control variables

Cell lines (DDLPS and leiomyosarcoma) derived from human surgical specimens
Cells maintained in RPMI medium 1640 with 10% fetal calf serum in a humidified incubator with 5% CO2 at 37 °C

controls

Positive control: IB115 cell line
Negative control: Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!